Tempest Therapeutics Inc

NASDAQ:TPST USA Biotechnology
Market Cap
$30.60 Million
Market Cap Rank
#30335 Global
#10004 in USA
Share Price
$2.27
Change (1 day)
+2.71%
52-Week Range
$0.50 - $11.83
All Time High
$3314.25
Categories
Companies in USA Biotechnology
About

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule du… Read more

Tempest Therapeutics Inc (TPST) - Net Assets

Latest net assets as of September 2025: $6.35 Million USD

Based on the latest financial reports, Tempest Therapeutics Inc (TPST) has net assets worth $6.35 Million USD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.13 Million) and total liabilities ($10.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $6.35 Million
% of Total Assets 37.05%
Annual Growth Rate 13.18%
5-Year Change N/A
10-Year Change -84.92%
Growth Volatility 233.29

Tempest Therapeutics Inc - Net Assets Trend (2011–2024)

This chart illustrates how Tempest Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Tempest Therapeutics Inc (2011–2024)

The table below shows the annual net assets of Tempest Therapeutics Inc from 2011 to 2024.

Year Net Assets Change
2024-12-31 $19.13 Million -28.55%
2023-12-31 $26.77 Million +47.80%
2022-12-31 $18.11 Million -49.85%
2021-12-31 $36.12 Million +152.50%
2020-12-31 $-68.79 Million -214.90%
2019-12-31 $59.87 Million -18.12%
2018-12-31 $73.12 Million +388.03%
2017-12-31 $14.98 Million -86.15%
2016-12-31 $108.22 Million -14.69%
2015-12-31 $126.85 Million +129.28%
2014-12-31 $55.33 Million +32.67%
2013-12-31 $41.70 Million +35.74%
2012-12-31 $30.72 Million +703.58%
2011-12-31 $3.82 Million --

Equity Component Analysis

This analysis shows how different components contribute to Tempest Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 20448200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $44.00K 0.23%
Other Components $226.19 Million 1182.62%
Total Equity $19.13 Million 100.00%

Tempest Therapeutics Inc Competitors by Market Cap

The table below lists competitors of Tempest Therapeutics Inc ranked by their market capitalization.

Company Market Cap
CPH Chemie + Papier Holding AG
LSE:0QNZ
 		$6.46 Million
Trigon Metals Inc
PINK:PNTZF
 		$6.46 Million
Regency Affiliates Inc
PINK:RAFI
 		$6.46 Million
ZUUZF
PINK:ZUUZF
 		$6.46 Million
Intraco Penta Tbk
JK:INTA
 		$6.45 Million
Pengana Capital Group Ltd
AU:PCG
 		$6.45 Million
HF Co.
LSE:0EOI
 		$6.45 Million
Concrete Engineering Products
KLSE:8435
 		$6.45 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tempest Therapeutics Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 26,768,000 to 19,126,000, a change of -7,642,000 (-28.5%).
  • Net loss of 41,843,000 reduced equity.
  • New share issuances of 28,591,000 increased equity.
  • Other factors increased equity by 5,610,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-41.84 Million -218.78%
Share Issuances $28.59 Million +149.49%
Other Changes $5.61 Million +29.33%
Total Change $- -28.55%

Book Value vs Market Value Analysis

This analysis compares Tempest Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.31x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.00x to 3.31x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2012-12-31 $15468.78 $2.27 x
2013-12-31 $414.30 $2.27 x
2014-12-31 $549.66 $2.27 x
2015-12-31 $1053.77 $2.27 x
2016-12-31 $757.41 $2.27 x
2017-12-31 $1907.53 $2.27 x
2018-12-31 $687.94 $2.27 x
2019-12-31 $64.07 $2.27 x
2020-12-31 $-2204.20 $2.27 x
2021-12-31 $123.87 $2.27 x
2022-12-31 $20.39 $2.27 x
2023-12-31 $1.74 $2.27 x
2024-12-31 $0.69 $2.27 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tempest Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -218.78%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 2.17x
  • Recent ROE (-218.78%) is above the historical average (-351.66%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2011 -71.28% 0.00% 0.00x 1.20x $-3.11 Million
2012 -43.98% 0.00% 0.00x 1.07x $-16.58 Million
2013 -69.65% 0.00% 0.00x 1.14x $-33.21 Million
2014 -89.51% -508.68% 0.15x 1.19x $-55.05 Million
2015 -57.72% -26432.85% 0.00x 1.09x $-85.90 Million
2016 -76.01% -12597.24% 0.01x 1.13x $-93.08 Million
2017 -3796.14% -28670.51% 0.01x 8.89x $-84.80 Million
2018 -38.33% 0.00% 0.00x 1.18x $-34.29 Million
2019 -76.12% 0.00% 0.00x 1.28x $-50.42 Million
2020 0.00% 0.00% 0.00x 0.00x $-12.24 Million
2021 -78.36% 0.00% 0.00x 2.03x $-31.91 Million
2022 -197.17% 0.00% 0.00x 2.54x $-37.52 Million
2023 -110.17% 0.00% 0.00x 1.93x $-32.17 Million
2024 -218.78% 0.00% 0.00x 2.17x $-43.76 Million

Industry Comparison

This section compares Tempest Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $59,082,939
  • Average return on equity (ROE) among peers: -341.19%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Tempest Therapeutics Inc (TPST) $6.35 Million -71.28% 1.70x $6.46 Million
Aadi Bioscience Inc (AADI) $-124.24K 0.00% 0.00x $17.03 Million
America Great Health (AAGH) $-992.37K 0.00% 0.00x $2.12 Million
Ascentage Pharma Group International (AAPG) $70.63 Million -1310.51% 34.40x $2.25 Billion
Aardvark Therapeutics, Inc. Common Stock (AARD) $-27.92 Million 0.00% 0.00x $59.18 Million
ABIVAX Société Anonyme (AAVXF) $196.01 Million -75.37% 0.67x $377.86 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $738.02 Million
Abeona Therapeutics Inc (ABEO) $489.00K -1919.02% 38.85x $202.79 Million
Acumen Pharmaceuticals Inc (ABOS) $188.78 Million -22.70% 0.04x $108.65 Million
Abpro Holdings, Inc. (ABP) $-22.46 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $176.18 Million -62.76% 0.23x $345.85 Million